tbuckley/cabot-search huggingface dataset:
Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).
Authors: Simon J. Crabb, Robert A Huddart, Emma Brown, Denise Dunkley, Nichola Downs, Cathy McDowell, James WF Catto, Gareth Owen Griffiths, Sarah Danson, Alison Helen Reid
Journal: Journal of Clinical Oncology (2020)

e17057 Background: Treatment options for platinum refractory GCTs are limited. Platinum resistance derives, in part, from tumour suppressor gene promotor methylation. In vitro, this reverses on co-administration of a DNA hypomethylating agent. Guadecitabine is a next generation hypomethylating agent. SPIRE is a phase Ib/IIa clinical trial to establish a GCG dose/schedule. Methods: We report 2 platinum refractory GCT patients (pts) treated (txd) in SPIRE with GCG (guadecitabine 20 mg/m 2 , SC, day (D) 1-5; cisplatin 70 mg/m 2 , IV, D8; gemcitabine 1000 mg/m 2 , IV, D8 + 15; filgrastim 300 μg, SC, D15-21; q21). Results: Pt 1: 21 yo man, testicular mixed GCT (seminoma/malignant teratoma intermediate). Prior tx: 2001, orchidectomy; 2005, 3 x BEP (bleomycin, etoposide, cisplatin) + retroperitoneal lymph node dissection. 2015, 2 x TI (paclitaxel, ifosfamide), 3 x TIP (cisplatin, ifosfamide, paclitaxel); 2016, 3 x HDCE (high dose carboplatin/ etoposide + autologous stem cell transplantation); 2017, 6 x GOP (gemcitabine, oxaliplatin, paclitaxel). In 2017, received 6 x GCG in SPIRE for CT confirmed lung metastases (mets) and rising β-hCG (human chorionic gonadotropin). Response: RECIST stable disease with metabolic CR on PET in lungs and &gt; 90% β-hCG reduction. In Cycle 6, pt developed symptomatic brain mets, treated with WBRT (40Gy, 20#) + cyberknife to the six mets completed 2018. Since 2018, ongoing complete marker and radiologic (brain and systemic) remission (20 months). Pt 2: 44 yo man, primary mediastinal non-seminomatous GCT. Prior tx: 2008, 4 x BEP + mediastinal mass resection; 2015, 4 x TIP; 2016, 1 x HDCE. In 2017, received 5 x GCG in SPIRE for a PET avid mediastinal/pulmonary relapse and AFP (alpha-fetoprotein) rise. Response: RECIST stable and &gt; 50% AFP reduction for 6 months (subsequent progression with intracerebral metastasis). Treatment was well tolerated. Grade 4 neutropenia/ thrombocytopenia occurred in both and febrile neutropenia in pt 1. Both required a 25% dose reduction in Cis/Gem. Conclusions: GCG produced exceptional clinical responses in both platinum refractory GCT pts. Prospective evaluation is warranted. Clinical trial information: 16332228.
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.
Authors: Alison M. Schram, Alexander E. Drilon, Teresa Macarulla, Eileen Mary O'Reilly, Jordi Rodon, Brian M. Wolpin, Sai-Hong Ignatius Ou, Dong-Wan Kim, James C. Yang, Justina Yick Ching Lam, Andrea Varga, Joop De Langen, Petronella Witteveen, Valentina Boni, Giulio Cerea, Michaël Duruisseaux, Stephen V. Liu, Ernesto Wasserman, Josep Tabernero
Journal: Journal of Clinical Oncology (2020)

TPS3654 Background: NRG1 fusions are oncogenic drivers across various cancers. NRG1 fusion proteins bind to HER3, leading to HER2/HER3 heterodimerization, increased downstream signaling, and tumor growth. Clinical responses to anti-HER3 antibodies or HER2 tyrosine kinase inhibitors have been reported. In contrast to these agents, MCLA-128 is a HER2/HER3 bispecific antibody that blocks both NRG1 binding and HER2/3 dimerization. Two patients with chemotherapy-resistant ATP1B1-NRG1-positive pancreatic KRAS-wild-type adenocarcinomas who received MCLA-128 through FDA-approved single-patient Investigational New Drug (IND) applications showed significant tumor shrinkage and durable tumor marker (CA-19-9) response. These data support the evaluation of MCLA-128 in NRG1 fusion-positive tumors using a basket approach. Methods: This is a global, open-label, multicenter phase 2 basket trial of MCLA-128 in patients with solid tumors harboring NRG1 gene fusions. Main eligibility criteria are locally advanced unresectable or metastatic cancers harboring an NRG1 fusion, and failure under prior standard therapy appropriate for the tumor type and disease stage. Genomic screening of tumor tissue is done at a local laboratory (with post-hoc central confirmation) or central laboratory (RNA sequencing). Three NRG1 fusion-positive tumor cohorts are being evaluated: pancreatic cancer, NSCLC, and other solid tumors. The sample size for the first two cohorts is up to 25 patients; the basket group may enroll up to 40 patients. The primary endpoint for all cohorts is investigator-assessed objective response rate (RECIST v1.1). The key secondary endpoint is duration of response. Other secondary endpoints include progression-free and overall survival. Eligible patients receive a bi-weekly dosing regimen of 750 mg of MCLA-128 (2-hour infusion), every 2 weeks, in 4-week cycles. The study is actively accruing patients in North America, Europe, and Asia. Previously presented at ESMO 2019, 685TiP, Schram et al.-Reused with permission. Clinical trial information: NCT02912949 .
有创与无创序贯机械通气治疗慢性阻塞性肺疾病致严重呼吸衰竭并多脏器功能损害三例
Authors: 杜玲玲, 陈小军, 张晓军
Journal: BMJ (2004)

例1 男性,62岁, 慢性阻塞性肺疾病(COPD)史30余年,加重伴呕吐咖啡样物于2002年10月19日入院.查体:重度发绀,嗜睡,两肺底湿性啰音,肝肋下2.5 cm.胸片:双肺下感染.动脉血气(吸氧 2 L/min):pH 值7.3,动脉血二氧化碳分压(PaCO2) 85.6 mmHg,动脉血氧分压(PaO2)23.1 mmHg,血钠138 mmol/L,血钾 4.5 mmol/L,血氯 91 mmol/L,血碱剩余 13.4, 血碳酸 45.8 mmol/L,血尿素氮 29.5 mmol/L,丙氨酸转氨酶(ALT) 874 U/L.诊断:呼吸性酸中毒代谢性碱中毒,多系统功能失代偿.即刻行气管插管机械通气,先后用容量辅助-控制(ACMV)、同步间歇指令(SIMV)+压力支持(PSV)+呼气末正压(PEEP)等呼吸模式,第9天痰色正常,痰量减少,体温正常,肺部湿性啰音减少,SIMV频率10次/min,PSV水平10 cm H2O,判断肺部感染控制窗出现,拔管改用鼻面罩通气,5 d后脱离呼吸机治疗,肝肾功能恢复正常。
肝癌其实可以预防
Authors: 杨秉辉
Journal: BMJ (2008)

据WH0统计,全世界每年发生肝癌50余万例,其中华人占半数以上!这个数字包括了海外华人,但必定绝大多数是生活在本土的中国人.我国城乡肝癌占全部恶性肿瘤发病率的第二、第三位,近年来肝癌发病的绝对数字还有增无减.众所周知,肝癌曾被称为癌中之王,如今虽然有了一些治疗的办法,但总体上的预后仍然很差,据估计全部肝癌的5年生存率不到5%。
Health behaviors (HBs) among head and neck cancer (HNC) survivors.
Authors: Linda A. Jacobs, Abigail N. Blauch, Donna A. Pucci, Steven C Palmer
Journal: Journal of Clinical Oncology (2020)

e24044 Background: HNC affects more than 59,000 Americans annually and is mediated by HBs both in terms of etiology and long term outcomes. Health behaviors in this population, however, have not been well described. This project describes HBs as a first step in developing appropriate interventions to improve health and, ultimately, outcomes among HNC survivors. Methods: Potential participants were identified through the tumor registry at the Abramson Cancer Center as well as affiliated sites. Eligibility included: a) Diagnosis and treatment of HNC; b) Aged 18 to 70 years; c) more than 1 year post-diagnosis; d) Confirmation of human papillomavirus (HPV) status; e) Ability to understand written English. Potential participants were sent an explanation of the study, informed consent, a self-reported questionnaire, and a self-addressed stamped envelope for return of materials. HBs included items recommended by Glasgow et al. assessing diet, aerobic activity, strength-flexibility, leisure time activity, smoking, alcohol consumption, and access to a physician. Results: 451 individuals were found to be eligible and approached. 102 (23%) agreed to participate and usable data were collected from 93 participants. The sample was predominantly white (96%), male (80%), middle aged (M = 59 yrs), married (82%), college educated (63%), and 63% reported an annual income of greater than $100,000. 74% were HPV positive. Although current smoking was rare (7%), historical use of tobacco was common (48%). Current alcohol use was also common (65%) with an average of 12 days per month in which alcohol was consumed. Participants reported an average of 2.1 drinks per day. Binge drinking was reported by 22% of those who drank, with an average of 3.5 binge drinking sessions per month. Scores on our measure of nutritional behavior range from 0-16 with lower scores indicating better nutrition. The sample mean was 7.1. According to body mass index (BMI) 59% were overweight or obese. With respect to the overall sample, 59% reported adequate aerobic exercise and 64% adequate strength and flexibility. In terms of leisure time activity, 18% would be classified as sedentary, 19% as moderately active, and 64% as active. All participants reported having a current primary care physician and 92% reported having had a physical examination in the previous 12 months. Conclusions: Binge drinking and BMI appear to be the most common negative HBs in this population, although there remain opportunities to improve dietary and exercise behaviors, as well.
婴儿喂养状况调查分析
Authors: 熊慧娟, 杨卫平, 靳丽娜
Journal: BMJ (2006)

2004年7月1日至2005年7月30日,对146例满4月龄婴儿家长进行了喂养现状及泥糊状食物添加的问卷调查.结果 显示4月龄母乳喂养率仅为43.8%;母亲所受教育程度不同对喂养知识的认知水平无明显影响;肥胖及超重儿的家长中78.3%认为自己婴儿的体重正常。
MMR deficiency of lung cancer patients.
Authors: Zongjuan Ming, Shuanying Yang, Jie Shi, Jun Bai, Xuemei Wei, Qiang Lu, Wei Li, Yujie Zhong, Xia Yang, Xin Lyu, Qingbo Wei, Dejian Gu, Rongrong Chen, Jingyan Yuan, Yang Chen
Journal: Journal of Clinical Oncology (2020)

e21523 Background: DNA Mismatch repair (MMR) plays an essential role in the genetic. The main function of MMR is thought to correct post replication errors since the system could recognizes base exchanges and short DNA insertions or deletions. Somatic mutation of MMR are common detected in lung cancer, and several studies has shown that the presence of MMR mutation may be resistance to EGFR-TKI. Here we retrospectively analyzed the MMR mutation in chinese lung cancer. Methods: We retrospectively analyzed the genetic aberration in 910 Chinese lung patients. All the patients were detected by hybridization capture-based NGS 1021-gene panel. Results: Here is an interesting lung cancer case which was called EGFR T790M, TP53 and MSH2 somatic mutations without any germline mutations, and this patient showed no response to Osimertinib. We retrospectively analyzed the MMR in 910 patients and called 39 patients with MMR mutation.The percence of MLH1, MLH2, MSH3, MSH6, PMS1 and PMS2 mutations rate is as followed: 10.3% (4/39), 33.3% (13/39), 7.7% (3/39), 28.2% (11/39), 5.1% (2/39), and 15.4% (6/39) cases in PMS2 mutation. Also we found that TP53 is the most highly concurrent gene for MRR deficiency the rate is 79.5%(31/39). The rate of EGFR mutation concurrent with MMR deficiency is 27% (10/39). Conclusions: MMR deficiency was found in 4.3% chinese lung cancer and 27% of them concurrent with EGFR. [Table: see text] [Table: see text] [Table: see text]
Contemporary survival trends and aetiological characterization in non‐ischaemic dilated cardiomyopathy
Authors: Marco Merlo, Antonio Cannatà, Carola Pio Loco, Davide Stolfo, Giulia Barbati, Jessica Artico, Piero Gentile, Valerio De Paris, Federica Ramani, Massimo Zecchin, Marta Gigli, Bruno Pinamonti, Renata Korcova, Andrea Di Lenarda, Mauro Giacca, Luisa Mestroni, Paolo G. Camici, Gianfranco Sinagra
Journal: European Journal of Heart Failure (2020)
宜昌地区尿路感染的细菌分布及耐药性分析
Authors: 马芹, 王群兴, 何晓雯, 周宜兰, 易虹, 王娟
Journal: BMJ (2006)

从我院尿培养的标本中分离出360株(男性44株,女性316株)细菌进行耐药性分析,分离前8位的细菌依次为大肠埃希菌(占45.6%),表皮葡萄球菌(占12.8%),粪肠球菌(占9.4%),腐生葡萄球菌(占3.8%),肺炎克雷伯菌(占3.3%),奇异变形杆菌(占2.8%),牛链球菌(占2.8%),产气肠杆菌(占2.2%);产超广谱β-内酰胺酶(ESBLs)细菌的检出率为12.5%,耐甲氧西林凝固酶阴性葡萄球菌(MRSCON)株为68.8%,高耐庆大霉素肠球菌(HLAR)株为40.0%,耐万古霉素肠球菌(VRE)株为4.0%;大肠埃希菌对亚胺培南、头孢哌酮/舒巴坦、阿米卡星、呋喃妥因敏感性较好(85.1%～100.0%),对氧氟沙星和青霉素类抗生素较差(18.3%～26.8%).过去常用于治疗尿路感染的喹诺酮类抗生素,耐药性较高。
Perception of anticoagulant treatment for atrial fibrillation in physicians from county-level hospitals
Authors: Changying Wang, Dayi Hu, Li Wang
Journal: BMJ (2015)

Objective
To investigate the perception of anticoagulant treatment for atrial fibrillation (AF) in physicians from county-level hospitals.


Methods
Two hundred and ninety two physicians from 9 hospitals of Jiangsu, Henan, Zhejiang, Jiangxi provinces were enrolled in this cross-sectional survey from June to November 2013. A standard questionnaire was used in the survey, which consisted of questions on knowledge, awareness and concerns of physicians regarding the diagnosis of atrial fibrillation and administration of warfarin.


Results
Total 292 questionnaires were returned and 208 of them were finally analyzed. According to the reports of the physicians, the percentage of anticoagulant treatment was 30.0% (10.0%-60.0%) in patients with rheumatic valvular AF, 20.0% (10.0%-50.0%) in patients with non-valvular AF and 80.0% (40.0%-100.0%) in those with mechanical heart valve replacement. The most common concerns of prescribing warfarin were worries about the bleeding related to warfarin (74.0%, 154), the necessary of monitoring INR (65.4%, 136) and advanced age (44.7%, 93). A half of physicians (51.0%, 106) thought that ECG was the main means for diagnosis of AF and only 28.3% (59) used both ECG and Holter as diagnosis procedure. Among the physicians who reported to use INR for monitoring warfarin administration, 62.5% (130) reported a target ranging 2-3 and one third reported a target INR <2. The proportion of the physicians who were aware of CHADS2 score and CHA2DS2-VASC score was 51.0% (106) and 41.3%(86), but only 15.4% (32) and 6.3% (13) of them knew the correct answer of the risk factors, respectively. Although 34.6% (72) physicians were aware of HAS-BLED score, only 5.3% (11) selected the 9 parameters correctly. 68.3% (142) physicians reported that vitamin K is the antidote for warfarin.


Conclusion
This study reveals the concerns and deficits in perception of anticoagulant treatment for AF patients in physicians of county-level hospitals, suggesting that education programs are needed to increase the prevalence of warfarin use in patients with AF.


Key words: 
Atrial Fibrillation; Questionnaives; Warfarin
Germline mutation in multiple primary malignancies associated with prostate cancer.
Authors: Yiming Gong, Liancheng Fan, Yinjie Zhu, Jiahua Pan, Jianjun Sha, Baijun Dong, Wei Xue, Jianqiang Lei, Jianfei Wang
Journal: Journal of Clinical Oncology (2020)

e17505 Background: Multiple primary malignancies (MPM) are described as that one individual develop several malignancies that originate from different tissues at the same time or separated (different histology in different location). MPM are also considered as an indicator of germline mutation or hereditary disease. Here we performed next generation sequencing-based 642-gene panel test on the MPM patients to figure out the candidate germline mutation essential for multiple tumorigenesis. Methods: Blood samples from 27 patients diagnosed as MPM with prostate cancer and at least one additional primary cancer from 2018.12 to 2019.12 were collected to detect the germline variation of 642 gene panel. Meanwhile 25 blood samples from patients only diagnosed as prostate cancer were taken as control. After the sequencing results were obtained, the differences between the multiple primary and single primary cohorts were counted. Results: Statistical analysis of the mutations in the multi-primary and single-primary cohorts revealed that differences were concentrated in the following six genes: ESR1, PTPRB, CIC, ANKRD11, BRCA2, MLH1. It was found that the mutations of p.G145S and p.P146Q (frequency 18.5%) of ESR1 gene and p.G1150W (frequency 14.8%) of PTPRB gene which related to angiogenesis were only found in multiple primary cohort. And mutations of growth factor pathway gene CIC (frequency 22.2%), mutation of chromatin remodeling family gene ANKRD11, and two genes of DDR pathway (BRCA2, MLH1) appeared higher in multiple primary cohort, although there was no statistical difference. Conclusions: We found for the first time that the p.G145S and p.P146Q mutations of the estrogen receptor ESR1 gene and the p.G1150W mutation of the angiogenesis-related PTPRB gene may be the drivers of multiple primary prostate cancer, which need further study.
Exposure to Pyrethroids and Health Risk
Authors: S. Eliza Dunn (Halcomb), Martin Cole, Larry Sheets
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
Authors: Mark Voskoboynik, Gary Edward Richardson, Linda R. Mileshkin, Catriona M. McNeil, Lisa Horvath, Fabio M. Benedetti, Gavin S. Choy, Neil Sankar, Shelly McCurry, Xiaoling Zhang, Min Gao, Ajit K. Shah, Michael Millward
Journal: Journal of Clinical Oncology (2020)

e15125 Background: APL-501 is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1). APL-501 is being evaluated in patients (pts) with advanced recurrent and relapsed solid tumors who had not been previously treated with an immune checkpoint inhibitor in an ongoing 3-part Phase 1 trial (NCT03053466). Herein, we present the emerging pharmacokinetic (PK) and receptor occupancy (RO), safety and preliminary efficacy. Methods: Weight-based dose escalation (1, 3, and 10 mg/kg, Part 1) and Extension (Part 2) has been completed and the study is currently enrolling specific tumor types (MSI-H/dMMR and Carcinoma of Unknown Primary [CUP]) into the Expansion Cohorts (Part 3). Relapsed/refractory solid tumor pts were enrolled in Part 1 and Part 2. Key exclusion criteria included prior therapy targeting PD-1/PD-L1 and uncontrolled CNS metastases. APL-501 was administered IV over 1 hour every 14 days. Serum and PBMCs were collected for PK and RO analysis, respectively. RO was assessed using different T-cell markers measured by flow cytometry of PBMC. Anti-tumor activity was assessed by investigators using RECIST and irRECIST. Safety was assessed using CTCAE, v4.03. Results: As of 31 Dec 2019, 22 pts were enrolled with a mean age of 62.1 (SD: 12.2) years. ECOG PS 0/1 reported at 10/12 pts, respectively. Pts had a median number of 3 prior lines of therapy (range, 1 – 9) and median time to treatment from initial diagnosis was 30.1 months (range, 6.7 – 184.8). Across doses evaluated, APL-501 demonstrated dose proportional PK. One hundred percent (100%) RO was observed across all doses evaluated. No dose limiting toxicities were reported. Fifteen pts (68.2%) had related AEs; two pts (9.1%) had Grade ≥ 3 related AEs to APL-501. Eight pts had stable disease and two pts had partial response by RECIST (esophageal adenocarcinoma and CUP). Seven pts remained on therapy for ≥ 24 weeks. The recommended phase 2 dose (RP2D) has been determined to be 400 mg IV every 14 days (non-weight-based) based on safety and PK modeling. Conclusions: Preliminary results indicate clinical activity of APL-501 in relapsed/refractory malignant disease with a generally tolerable safety profile. The PK and RO profile, across all doses evaluated, appears comparable to marketed PD-1 inhibitors. Continued exploration of APL-501 with the RP2D in CUP and MSI-H/dMMR tumors is being planned. Clinical trial information: NCT03053466 .
The serum level of the components of the renin-angiotensin system correlates with its tumor tissue expression in kidney cancer patients.
Authors: Roman Osokin, Ekaterina Komarova, Igor Aboyan, Aleksey Yu. Maksimov, Natalya D. Ushakova, Roman Ischenko, Olga Shatova, Elizaveta Komarova
Journal: Journal of Clinical Oncology (2020)

e17068 Background: To date, it has not been decided whether the locally-generated components of the renin-angiotensin system (RAS) involved in the pathogenesis of kidney cancer and arterial hypertension, and are local and systemic RAS related? The aim was to assess the relationship of the level of RAS in the tumor tissue and peripheral blood in patients with localized kidney cancer with arterial hypertension. Methods: In patients with localized kidney cancer T1N0M0 (KС) and arterial hypertension of the I-II stage (AH), tissue and serum levels of angiotensin I, angiotensin II, angiotensin (1-7), as well as angiotensin converting enzymes (ACE and ACE2) were determined in the following groups: patients with KC without AH (n = 35, KC) and with concomitant AH (n = 30; KC+ AH). The normative values of peripheral blood indices were revealed in healthy donors (n = 30). Results: The level of all studied RAS peptides in the serum of patients with KC was increased in comparison with healthy donors regardless of concomitant hypertension, and the activity of both circulating angiotensin-converting enzymes, on the contrary, was increased only in patients with hypertension. The level of AT1 exceeds the control indicators by 1.7 times (KC) and 2.8 times (KC + AH). The formation of AT2 is higher in the KC + AH compared to KC (2.2 times versus 1.7 times, at p &lt; 0.05). The content of AT (1-7) significantly exceeds the control (1.3 times on average, p &lt; 0.05) and higher in the KC + AH. Increased enzyme activity was detected in KC + AG: increased by 1.5 times (p &lt; 0.05) and 1.7 (p &lt; 0.05) compared with the control for ACE and ACE2, respectively. The pair correlation coefficients between the serum RAS and the studied tissues in the KC were: for AT1 -0.78/0.65; АТ2-0.64/0.59 and АТ (1-7) - 0.56/0.51; ACE2 0.55/0.65 (for tumor/peritumoral tissue: in all cases at p &lt; 0.05). In the KC+AH, these ratios were: for AT1 -0.85/0.81; АТ2-0.72/0.74 and АТ (1-7) - 0.65/0.59; ACE2 0.61/0.52 (for tumor / peritumoral tissue: in all cases at p &lt; 0.05). Conclusions: The serum content of RAS peptides had positive statistical relationships with the corresponding parameters in tumor and peritumoral tissues of kidney cancer pts. However, in hypertensive patients with kidney cancer the correlations found had a tightness of higher strength. Positive correlations of the level of locally generated tumor parameters of RAS with their circulating analogues indicate the possibility of their use as diagnostic markers of the development of kidney cancer.
Survey of recognition level of osteoporotic risk factors among community health service staff in Beijing
Authors: Su Yu, Xue-ping Du
Journal: BMJ (2013)

To survey the current awareness of risk factors for osteoporosis in community health staff in Beijing. A total of 200 medical staff including general practitioners, community nurses and public health doctors from 4 Community Health Service Centers in Beijing were examined by purposeful sampling. Then their knowledge of osteoporosis risk factors was gauged by a questionnaire. The community health staff lacked a sufficient knowledge of osteoporotic risk factors. And the most knowledgeable factor was advanced age of which 41.5% community health staff knew. The community health staff has an insufficient knowledge of osteoporosis so that its proper training should be strengthened.


Key words: 
Osteoporosis; Risk factors
基层医院的糖尿病患者教育体会
Authors: 成娟, 王福杰
Journal: BMJ (2006)

糖尿病(DM)的患病率在全球范围内呈不断上升趋势.[1],糖尿病教育是糖尿病治疗指南中必不可少的治疗手段,能使患者增长知识,阻止糖尿病慢性并发症的发展.[2].但在基层医院就诊的DM患者接受DM教育的人数很少,对疾病的认识有很多误区,应引起广大医务工作者的关注.现将本院近3年来对DM住院患者进行健康教育情况报告如下。